NEW YORK, NY / ACCESSWIRE / December 19, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on PixarBio Corporation (OTCQX: PXRB).
The report is available here: PXRB Update Note.
Based in Cambridge, MA, PixarBio Corporation (OTCQX: PXRB, "PixarBio") is a specialty pharmaceutical company focused on pre-clinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease™ is a non-opioid / non-opiate pre-clinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease™ blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy. There are numerous potential milestones for PixarBio over the next several quarters. The company has several planned clinical studies for NeuroRelease™ in 2017, and CEO Frank Reynolds has stated that PixarBio is also pursuing an uplisting to a national exchange, such as the Nasdaq CM or NYSE MKT.
Highlights from the note include:
PixarBio makes play to acquire InVivio (NVIV)
PixarBio began the year with an announcement that it is pursuing an acquisition of InVivio TherapeutIcs (NVIV). InVivio was founded in 2005 by current PixarBio CEO Frank Reynolds, who served as CEO until resigning in 2013. PixarBio is focused on developing NeuroRelease™ as a non-opioid treatment for post-surgical pain, and sees potential synergies for addressing neurotrauma by combining the InVivio's and PixarBio's research and development pipelines. We note that the offer is in stock, with PixarBio being listed over the counter, and InVivio trading on the Nasdaq, at a ratio implying a takeunder.
If PixarBio is ultimately successful in its bid to acquire InVivio, PXRB stated that the combined company will be renamed Reynolds Therapeutics. PixarBio CEO Frank Reynolds stated that Reynolds Therapeutics will be focused on acute and chronic pain, spinal cord injury, adaptive technologies, epilepsy, and Parkinson's disease. Readers should be aware that there has been animosity between Reynolds and InVivio management, including the dispute over the inventor status of several patents related to the NeuroScaffold.
PixarBio expands portfolio, targeting 2019E for first release
Outside of the intriguing corporate action developments described above, PixarBio continues to advance its pre-clinical development portfolio. On January 9, 2017, the company announced that it was investigating non-opioid pain treatments using steroid based injections. The steroid based injections are being investigated for the treatment of chronic and acute pain for up to 90 days.
PixarBio expects the first NeuroRelease™ product FDA decision will be for 14-day post-surgical pain treatment and is hopeful that it will obtain approval in time for commercial launch in 2019, using a 505(b)2 pathway. PixarBio's NeuroRelease™ pain platform also includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments; management is optimistic that it will be able to obtain FDA approval for these treatments by 2020.
Price target, estimates unchanged
Our price target and estimates are unchanged at this time. We will continue to monitor developments at PixarBio, including its bid for InVivio, and, more, importantly, clinical developments for its lead candidate, NeuroRelease™.
Please review important disclosures at www.seethruequity.com.
About PixarBio Corporation
PixarBio (OTCQX: PXRB) is a public company traded on the OTC markets under the stock symbol PXRB. PixarBio is a specialty pharmaceutical/biotechnology company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson's disease, and spinal cord injury. Our lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models. For more information, visit Pixarbio.com.
About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.
SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.
For more information visit www.seethruequity.com.
Contact:
SeeThruEquity
[email protected]
SOURCE: SeeThruEquity